(RVNC)—MYL’s decision whether to opt in for the Botox-biosimilar program is expected by the end of May.
Re-iterated on MYL’s RBC webcast yesterday. RVNC furnished analysis for MYL to evaluate on 4/29/30, and the contract allows MYL thirty days to make a decision.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”